Phase II Study of Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 86
- 试验地点
- 1
- 主要终点
- Clinical Benefit rate (CBR)
研究概览
简要总结
This is a prospective, single-arm, multi-center clinical study of pyrotinib in combination With letrozole in patients With HER2-Positive, ER-Positive metastatic breast cancer. Our aim was to explore the efficacy and safety of pyrotinib combined with letrozole in patients with HER2-positive, ER-positive metastatic breast cancer.
详细描述
ER+/HER2+ metastatic breast cancer is a special subtype of HER2+ breast cancer. General guidelines recommend chemotherapy combined with HER2-targeted therapy for this subtype of patients. However, for the highly selected patients with ER- positive/HER2-positive ABC, ET + anti-HER2 therapy could be chosen as first-line therapy. And Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. Therefore this study is planned to enroll 86 patients with HER2-positive, ER-positive metastatic breast cancer receiving first-line treatment with pyrotinib and letrozole. The main purpose was to evaluate the efficacy and safety of pyrotinib combined with letrozole in patients with HER2-positive, ER-positive metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with HER2+/ER+ recurrent or metastatic breast cancer confirmed by histopathology;
- •HER2 positive: HER2 IHC 3+, or HER2 IHC 2+ and ISH positive
- •ER positive: the percentage of cells positive for ER expression ≥ 10%
- •Premenopausal, perimenopausal or postmenopausal patients (with OFS, if pre- or perimenopausal);
- •If the patient is bilateral breast cancer, metastasis lesions must be HER2 and ER positive;
- •18-70 years old;
- •ECOG PS 0～1;
- •Life expectancy is not less than 12 weeks;
- •At least one measurable lesion according to RECIST 1.1;
- •Prior (neo) adjuvant trastuzumab, pertuzumab or chemotherapy were eligible, and the disease free interval must be greater than 12 months from completion of (neo) adjuvant trastuzumab and pertuzumab to metastatic diagnosis;
- •Prior (neo) adjuvant hormone therapy was allowed, if received adjuvant AI, the disease free interval must be greater than 12 months from the completion of treatment;
- •Disease-free Survival after surgery (DFS) ≥12 months;
- •Patients with adequate organ function before enrollment: ANC ≥ 1.5×109/L, PLT ≥ 75×109/L, Hb ≥ 100 g/L; TBIL≤1.0ULN；ALT and AST≤3×ULN (ALT and AST≤5×ULN if liver metastasis); BUN and Cr≤1.5×ULN and CCr≥50 mL/min; LVEF ≥ 50% and QTc < 480 ms;
- •Signed informed consent.
排除标准
- •Central nervous system metastasis;
- •patients with Visceral crisis;
- •Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption;
- •received radiotherapy, hormone therapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy for advanced or metastatic disease;
- •received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks prior to randomization;
- •Received hormone therapy within 2 weeks prior to randomization;
- •Participated in other clinical trial within 4 weeks prior to randomization;
- •Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors (lapatinib, neratinib or pyrotinib);
- •Other malignancies within 5 years, except for cured skin basal cell carcinoma,carcinoma in-situ of uterine cervix and squamous-cell carcinoma;
- •Receive other anti-tumour therapy at the same time;
- •History of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known;
- •History of any kind of Heart disease;
- •All female patients in pregnancy or breastfeeding period, fertile women with positive baseline pregnancy tests;
- •Evidence of significant medical illness that will substantially increase the risk on the participation or completion of the study in the investigator's judgment. Examples included, but not limited to, hypertension, severe diabetes, etc;
- •History of neurological or psychiatric disorders, including epilepsy or dementia;
- •Patients not eligible for this study judged by the investigator.
研究组 & 干预措施
Pyrotinib plus Letrozole
干预措施: Pyrotinib Maleate plus Letrozole (Drug)
结局指标
主要结局
Clinical Benefit rate (CBR)
时间窗: Estimated 12 months
Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects
次要结局
- Objective Response Rate (ORR)(Estimated 12 months)
- Progression Free Survival (PFS)(Estimated 12 months)
- Overall Survival (OS)(Estimated 24 months)
- Adverse Events and Serious Adverse Events(From informed consent through 28 days following treatment completion)